Practice
Primary care for recipients of allogeneic hematopoietic stem cell transplantation
Jill Fulcher, Sherrie Hertz and Christopher Bredeson
CMAJ November 23, 2020 192 (47) E1538; DOI: https://doi.org/10.1503/cmaj.200160
Jill Fulcher
Ottawa Hospital Research Institute, Department of Medicine (Fulcher, Bredeson), University of Ottawa, Ottawa, Ont.; Clinical Programs and Quality Initiatives (Hertz), Cancer Care Ontario, Toronto, Ont.
MDSherrie Hertz
Ottawa Hospital Research Institute, Department of Medicine (Fulcher, Bredeson), University of Ottawa, Ottawa, Ont.; Clinical Programs and Quality Initiatives (Hertz), Cancer Care Ontario, Toronto, Ont.
BScPhmChristopher Bredeson
Ottawa Hospital Research Institute, Department of Medicine (Fulcher, Bredeson), University of Ottawa, Ottawa, Ont.; Clinical Programs and Quality Initiatives (Hertz), Cancer Care Ontario, Toronto, Ont.
MDArticle Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Respond to this article
Primary care for recipients of allogeneic hematopoietic stem cell transplantation
Jill Fulcher, Sherrie Hertz, Christopher Bredeson
CMAJ Nov 2020, 192 (47) E1538; DOI: 10.1503/cmaj.200160
Jump to section
- Article
- Hematopoietic stem cell transplantation offers the chance of cure for myelodysplastic syndrome, myeloproliferative neoplasms and most adult acute leukemia and relapsed lymphoma
- Optimal care after transplant involves a collaboration among the SCT centre, the primary care provider and the patient
- Compared with the general population, SCT recipients have 4 times the risk of CVD
- As a result of prior therapy, SCT recipients have up to 5 times the risk of a secondary malignancy compared with the general population
- Prior immunity is lost after transplant, and revaccination is necessary from 3 months after the procedure
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.